Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up

Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavakoli, Sahar, Khalaj, Fattaneh, Kasaeian, Amir, Mousavi, Seyed Ali, Mousavian, Amir-Hossein, Arabi, Fatemeh, Rad, Soroush, Rostami, Shahrbano, Barkhordar, Maryam, Biglari, Mohammad, Mardani-Fard, Heydar Ali, Alemi, Hediyeh, Khavandgar, Naghmeh, Kamranzadeh Fumani, Hossein, Janbabai, Ghasem, Mousavi, Seied Asadollah, Ghavamzadeh, Ardeshir, Vaezi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076610/
https://www.ncbi.nlm.nih.gov/pubmed/37013251
http://dx.doi.org/10.1177/09636897231163212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076610/
https://www.ncbi.nlm.nih.gov/pubmed/37013251
http://dx.doi.org/10.1177/09636897231163212

Ejemplares similares